Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/1 cls
Achillion (ACHN) Susquehanna Jason Kolbert New Net positive 9% $15.25
Kolbert said ACHN's technology was validated by a 2004 HCV partnership with Gilead (GILD) (see BioCentury, Dec. 6, 2004). He expects catalysts in 1H07 to include Phase II data for lead compound elvucitabine, a nucleoside reverse transcriptase inhibitor for HIV.
Advanced Magnetics (AMAG) Jefferies Adam Walsh Price target Buy 3% $59.10
ThinkEquity Vinny Jindal Price target Buy
Walsh raised his target to $82 from $73 after AMAG's IV ferumoxytol met the primary endpoint of a significant mean change in hemoglobin from baseline in a Phase III trial to treat anemia in patients with chronic kidney disease (CKD) (see BioCentury,

Read the full 1225 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE